Recursion Pharmaceuticals Inc
NASDAQ:RXRX
Recursion Pharmaceuticals Inc
In the bustling landscape of biotech innovation, Recursion Pharmaceuticals Inc. carves a distinctive niche by marrying the worlds of biology and advanced computational techniques. Founded in 2013, this Salt Lake City-based company embarked on a mission to decode the complex tapestry of disease biology through the lens of data science and machine learning. Recursion's approach centers around its unique platform that integrates automated experimental biology with artificial intelligence to map and navigate the intricate pathways of human cellular biology. By harnessing volumes of data from high-throughput biological experiments, they aim to unearth novel insights into a multitude of diseases, particularly those that have historically evaded effective therapeutic intervention.
At the heart of Recursion's business model is its ability to discover potential drug candidates rapidly and efficiently, turning traditional pharmaceutical development on its head. The company generates revenue through strategic partnerships with pharmaceutical giants, leveraging its platform to accelerate drug discovery and development processes. Collaborations often involve sharing the risk and reward of drug discovery, with Recursion providing the technological backbone to sift through vast datasets and identify promising therapeutic compounds. Additionally, Recursion invests in its pipeline of proprietary drug candidates, targeting rare genetic diseases and areas of significant unmet medical need. By aligning cutting-edge technology with the complexities of human biology, Recursion Pharmaceuticals positions itself at the forefront of transforming how diseases are understood and how new treatments are developed.
In the bustling landscape of biotech innovation, Recursion Pharmaceuticals Inc. carves a distinctive niche by marrying the worlds of biology and advanced computational techniques. Founded in 2013, this Salt Lake City-based company embarked on a mission to decode the complex tapestry of disease biology through the lens of data science and machine learning. Recursion's approach centers around its unique platform that integrates automated experimental biology with artificial intelligence to map and navigate the intricate pathways of human cellular biology. By harnessing volumes of data from high-throughput biological experiments, they aim to unearth novel insights into a multitude of diseases, particularly those that have historically evaded effective therapeutic intervention.
At the heart of Recursion's business model is its ability to discover potential drug candidates rapidly and efficiently, turning traditional pharmaceutical development on its head. The company generates revenue through strategic partnerships with pharmaceutical giants, leveraging its platform to accelerate drug discovery and development processes. Collaborations often involve sharing the risk and reward of drug discovery, with Recursion providing the technological backbone to sift through vast datasets and identify promising therapeutic compounds. Additionally, Recursion invests in its pipeline of proprietary drug candidates, targeting rare genetic diseases and areas of significant unmet medical need. By aligning cutting-edge technology with the complexities of human biology, Recursion Pharmaceuticals positions itself at the forefront of transforming how diseases are understood and how new treatments are developed.
Proof of Concept: Recursion reported its first positive AI-enabled clinical proof of concept with FAP, a disease with no approved therapies, showing significant and durable reduction in polyp burden.
Sanofi Partnership: The company achieved its fifth milestone with Sanofi, delivering five lead packages and totaling $134 million in upfront and milestone payments from this collaboration.
Cost Discipline: Operating expenses were reduced by 35% year-over-year, coming in 10% below prior guidance, enabling cash runway extension into early 2028.
Pipeline Progress: Multiple programs are advancing, with key FDA engagement for REK481 on track for the first half of 2026, and go/no-go decisions for PI3K and ENPP1 expected in the second half of 2024.
Platform Efficiency: Recursion’s AI platform enabled compound synthesis at 90% fewer compounds and twice the speed versus industry standards, and improved clinical trial enrollment rates by 1.3–1.6x.
Financial Strength: The year ended with $754 million in cash and expected 2026 cash operating expenses below $390 million.
